National Cancer Institute bioassay program

National Cancer Institute. Bioassay of Toxaphene for Possible Carcinogenicity. DHEW (NIH) Pub No 79-837. Bethesda, MD, Carcinogenesis Testing Program, Division of Cancer Cause and Prevention, 1979... 

NCI. 1979. Bioassay of methyl parathion for possible carcinogenicity. Bethesda, MD U.S. Department of Health, Education, and Welfare, National Institutes of Health, National Cancer Institute, Carcinogenesis Testing Program. DHEW (NIH) Publication No. 79-1713 NCI-CG-TR-157, 112. 

NCI. 1976. Carcinogenesis bioassay of trichloroethylene (CAS No. 79-01-6). Bethesda, MD National Cancer Institute, Division of Cancer Cause and Prevention, Carcinogenesis Program, Carcinogen Bioassay and Program Resources Branch. NCI-CG-TR-2, DHEW Publ. No. (NIH) 76-802. 

NCI. 1976. Report on carcinogenesis bioassay of chloroform. Bethesda, MD Carcinogenesis Program, National Cancer Institute. 

NCI/NTP. 1979a. Bioassay of 2,7-dichlorodibenzo-p-dioxin (DCDD) for possible carcinogenicity. Bethesda MD US. Department of Health, Education, and Welfare, Public Health Service, National Cancer Institutes/National Toxicology Program. (NIH) DHEW Publication no. 79-1378. 

Weissburger, E.K. History of the bioassay program of the national cancer institute. Progr. Exp. Tumor Res. 1983, 26, 187-201. 

NCI. 1978. Bioassay of 4-amino-2-nitrophenol for possible carcinogenicity. National Cancer Institute, Technical Report Series No. 94. Carcinogenesis Testing Program, National Cancer... 

U.S. National Cancer Institute belong to this category. Such bioassays are most powerful when they are used, as in the N.C.I. program, to discover leads with unusual profiles of activity [3], but the implementation of a panel of multiple cell lines is labor-intensive and thus costly. Compounds which show non-selective cytotoxicity do not turn out to have useful in vivo activity thus recent compilations of anticancer natural products [4 - 6] contain many examples of compounds with no documented in vivo activity. 

Recent advances in the discovery of novel anticancer agents from higher plants are reported. These compounds are uncovered based on bioassay-directed fractionation and tandem MS analysis to detect analogs of significant lead compounds. The evolution and current status of the screening program of the U.S. National Cancer Institute is reviewed. 

---